Kailera Therapeutics, Inc.

Filing Date

Apr 16, 2026

Transaction Date

Apr 16, 2026

Accession Number

0001193125-26-159766

Form Type

3

Footnotes

1. (F1)Each share of the Issuer's Series B Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.
2. (F2)Represents shares of the Issuer's Series B Preferred Stock held directly by BCPE Perseus Investor, LP ("BCPE Perseus").
3. (F3)Bain Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.